Dr. S. Duarte graduated in Nutrition from the Universidade Paulista in 2007, got a Master in Clinical Gastroenterology Program at the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO in 2015 and became Doctor of Science in Gastroenterology from the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (2019) . He is currently a professor of undergraduate classes at Universidade Paulista. Has a background in nutrition, with a focus on gut microbiota assessment in Non-Alcoholic Fatty Liver Disease (NAFLD).
Dr. S Duarte
Surveillance in patients with non-cirrhotic NAFLD-related HCC: obstacles and solutions
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease encompassing simple hepatic steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC).
Read MoreThe PPARα-FABP1 axis: a new target for NASH therapies?
Although it is known that non-alcoholic steatohepatitis (NASH) increases the risk of end-stage liver diseases such as cirrhosis and hepatocellular carcinoma, no pharmacologic therapy has yet been approved to treat it.
Read MoreEmerging therapies for NASH: an overview of promising targets
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 25% of the world’s adult population. In 20% of these patients, NAFLD further develops into non-alcoholic steatohepatitis (NASH), which itself represents a leading cause of progression to liver cirrhosis and hepatocellular carcinoma.
Read MorePlasma TREM2: a promising non-invasive biomarker for NASH?
Although liver biopsy is the gold standard for the identification of non-alcoholic steatohepatitis (NASH), limits associated with its invasiveness justify research into non-invasive markers.
Read MoreImmune mechanisms behind NAFLD-associated inflammation
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and a significant contributor to liver cirrhosis, transplantation, and hepatocellular carcinoma.
Read MoreGlobal prevalences of NAFLD, NAFL and NASH in the overweight and obese population
Non-alcoholic fatty liver disease (NAFLD) is currently the fastest-growing indicator for liver transplantation worldwide. Its status as a growing health concern further parallels the global rise of obesity.
Read MoreNAFLD: a growing burden with a rising global prevalence?
Data from the Global Burden of Disease study indicates that non-alcoholic fatty liver disease (NAFLD) is the most rapidly increasing global contributor to chronic liver disease (CLD)-associated complications, which include the onset of cirrhosis and hepatocellular carcinoma.
Read MoreEffects of mitochondrial transplant therapy on the reparation of injured skeletal muscle
It is known that traumatic muscle injury damages mitochondria, which may cause them to leak their contents into the cytoplasm and subsequently trigger calcium accumulation, cell death, endoplasmic reticulum stress, and the release of reactive oxygen species (ROS).
Read MoreDaily walking speed and frailty: a significant association?
Walking speed (WS) is clinically recognized as a crucial vital sign. Associations between daily walking speed (DWS) and health outcomes have been underscored by a number of studies, which have further recognized it as an accurate predictor of dependency and mortality in elderly individuals. Despite this knowledge, very few studies have examined the link between DWS and frailty.
Read MoreA multidisciplinary approach to NAFLD-centred care
The association between metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) has been well-characterised by recent literature. As such, patients with NAFLD are disproportionately affected by a range of comorbidities, which include obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and hypertension.
Read MoreThe FAST score for fibrotic NASH: a useful non-invasive tool?
A non-invasive combined model termed FibroScan-aspartate aminotransferase (FAST) was recently proposed for the diagnosis of fibrotic non-alcoholic steatohepatitis (NASH). Conceptualised for patients with elevated non-alcoholic fatty liver disease (NAFLD) activity scores (≥4) and significant fibrosis
Read MoreUnderstanding the clinical benefits of cirrhosis regression in NASH
Cirrhosis is the end stage of a number of chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Characterised by the scarring of liver tissue, cirrhosis leads to significant hepatic tissue distortion, which may subsequently cause portal hypertension, hepatic synthetic dysfunction, and hepatocellular carcinoma.
Read More
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES